FeesSafety
Pluang+

BlackRock buys $276M in Bitcoin amid weak institutional demand and market dip

Market News
29 Oct 2026, 17:00 WIB
AMBCrypto
View Source
Neutral
BlackRock buys $276M in Bitcoin amid weak institutional demand and market dip

Bitcoin has been trading between $79k and $81k after a failed attempt to rise above $84.9k. Despite this, BlackRock's IBIT Bitcoin ETF has bought over 3,441 BTC worth $276.7 million in the past three days, signaling strong ETF interest. However, overall institutional demand remains weak, especially from U.S. investors, which could prolong market weakness and push prices down to $76k. Continued BlackRock purchases might help Bitcoin hold $80k and aim for $84k.

BlackRock's IBIT Bitcoin ETF shows strong recent buying with $276.7 million in Bitcoin. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 29, 2026 21:22 WIB: 26 of 50 major cryptocurrencies rose today. Notable movers include MANA at Rp1.400 with a 1-day change of -1.96% and 95% buy order activity, FIL at Rp16.434 up 1.88% with balanced orders, and LUNC at Rp0,809 down 1.82% with 90% sell orders.

More News

Anthropic plans IPO to fund AI-driven bioscience, with potential future ties to Ginkgo Bioworks' lab automation.

Anthropic plans IPO to fund AI-driven bioscience, with potential future ties to Ginkgo Bioworks' lab automation.

Anthropic is set to go public on November 19, raising tens of billions to boost its AI capabilities in bioscience, focusing on lab automation and robotics. Ginkgo Bioworks, a leader in automated biotech labs, collaborates with OpenAI but has no curre...

Market News
Bullish
27 minutes ago
BellRing shares jump 24% on strong sales and upbeat earnings forecast

BellRing shares jump 24% on strong sales and upbeat earnings forecast

BellRing Brands saw a 24% surge in its stock price after reporting a 7% increase in net sales to $692 million for fiscal 2026 Q4, driven by strong demand for its high-protein Premier Protein shakes and new product launches like Sparkling Protein Soda...

Company Fundamentals
Bullish
31 minutes ago
Analyst cuts Peabody Energy price target by nearly 30% but keeps buy rating.

Analyst cuts Peabody Energy price target by nearly 30% but keeps buy rating.

Freedom Broker analyst Vitaly Kononov lowered Peabody Energy's price target from $30 to $22 per share, citing reduced production outlooks at its key Centurion coal mine and vulnerability in coal prices. Despite the significant cut, he maintained a bu...

Analyst Insights
Bearish
1 hour ago
Micron's strong growth and rising stock price hint at a possible future stock split.

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron Technology is showing strong financial growth, driven by its crucial role in AI infrastructure and multiyear deals with key tech companies. The company recently beat revenue expectations with a 379% year-over-year increase and projects even be...

Company Fundamentals
Bullish
1 hour ago
FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

The FDA has approved Livsayis™ (cemdisiran), the first and only siRNA therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive. This subcutaneous treatment, administered four times a year, targ...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App